Chasing Pfizer, Sarepta Prepares To Launch Pivotal Duchenne Gene Therapy Trial

Investors Still Skeptical

 
• By Andrew McConaghie
  
Sarepta building
Sarepta already has three DMD products on the market, but analysts believe gene therapies are more likely to represent progress against the muscle-wasting disease. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies